Browse Arkansas Code titles and sections
22 U.S.C. § 7653 — Report on treatment activities by relevant executive branch agencies
Federal law — U.S. Code and appendices · legal_authorities
**(a) In general** Not later than 15 months after May 27, 2003, the President shall submit to appropriate congressional committees a report on the programs and activities of the relevant executive branch agencies that are directed to the treatment of individuals in foreign countries infected with HIV or living with AIDS.
**(b) Report elements** The report shall include—
(1) a description of the activities of relevant executive branch agencies with respect to—
(A) the treatment of opportunistic infections;
(B) the use of antiretrovirals;
(C) the status of research into successful treatment protocols for individuals in the developing world;
(D) technical assistance and training of local health care workers (in countries affected by the pandemic) to administer antiretrovirals, manage side effects, and monitor patients’ viral loads and immune status;
(E) the status of strategies to promote sustainability of HIV/AIDS pharmaceuticals (including antiretrovirals) and the effects of drug resistance on HIV/AIDS patients; and
(F) the status of appropriate law enforcement officials working to ensure that HIV/AIDS pharmaceutical treatment is not diminished through illegal counterfeiting and black market sales of such pharmaceuticals;
(2) information on existing pilot projects, including a discussion of why a given population was selected, the number of people treated, the cost of treatment, the mechanisms established to ensure that treatment is being administered effectively and safely, and plans for scaling up pilot projects (including projected timelines and required resources); and
(3) an explanation of how those activities relate to efforts to prevent the transmission of the HIV infection.
Source: Supplied U.S. Code snapshot — release unconfirmed · 22 U.S.C. § 7653
Stored review status: release_metadata_unconfirmed. A text match is a research starting point; applicability is not established.
Original supplied file — preserved unchanged
Download original Markdown file
File SHA-256: 03645e01ff000f464d4d928ce7e641e61a788cf1d3af2d3d8118af9cabc7a081. The original may include catalog metadata, neighboring provisions, or embedded records outside this collection's scope. Search shows only the selected federal record. Historical editions and unverified snapshots are not a statement of current law.
Authority boundary: historical or unconfirmed source not current law verified.
Open the recorded source website ↗
Record provenance
Stable record: federal_law:legal_authorities:record_usc_e7c50e11591bb99e79278613
Source file: Laws/federal/codes/united-states-code/title-22/section-7653-report-on-treatment-activities-by-relevant-executive-branch-agencies--a3ffbe7d23.md
Pages: Not recorded – Not recorded
Passage SHA-256: 0332ee2cc15efa69b8b4c4ba8352b15ea191a2430d5ac8e9c049c721d26cb478
Source location: Title 22, Chapter 83, § 7653; chapter-083-united-states-leadership-against-hiv-aids-tuberculosis-and-malaria.md
Stored source content
**(a) In general** Not later than 15 months after May 27, 2003, the President shall submit to appropriate congressional committees a report on the programs and activities of the relevant executive branch agencies that are directed to the treatment of individuals in foreign countries infected with HIV or living with AIDS.
**(b) Report elements** The report shall include—
(1) a description of the activities of relevant executive branch agencies with respect to—
(A) the treatment of opportunistic infections;
(B) the use of antiretrovirals;
(C) the status of research into successful treatment protocols for individuals in the developing world;
(D) technical assistance and training of local health care workers (in countries affected by the pandemic) to administer antiretrovirals, manage side effects, and monitor patients’ viral loads and immune status;
(E) the status of strategies to promote sustainability of HIV/AIDS pharmaceuticals (including antiretrovirals) and the effects of drug resistance on HIV/AIDS patients; and
(F) the status of appropriate law enforcement officials working to ensure that HIV/AIDS pharmaceutical treatment is not diminished through illegal counterfeiting and black market sales of such pharmaceuticals;
(2) information on existing pilot projects, including a discussion of why a given population was selected, the number of people treated, the cost of treatment, the mechanisms established to ensure that treatment is being administered effectively and safely, and plans for scaling up pilot projects (including projected timelines and required resources); and
(3) an explanation of how those activities relate to efforts to prevent the transmission of the HIV infection.
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Delegation by President; rules and regulations; utilization of goods and services from private enterprise, and facilities and resources of Federal agencies when not competitive with private enterprise** The President may exercise any functions conferred upon him by this chapter through such agency or officer of the United States Government as he shall direct. The head of any such agency or such officer may from time to time promulgate such rules and regulations as may be necessary to carry out such functions, and may delegate authority to perform any such functions, including, if he shall so specify, the authority successively to redelegate any of such functions to any of his subordinates. In providing technical assistance under this chapter, the head of any such agency or such officer shall utilize, to the fullest extent practicable, goods and professional and other services from private enterprise on a contract basis. In such fields as education, health, housing, or agriculture, the facilities and resources of other Federal agencies shall be utilized when such facilities are particularly or uniquely suitable for technical assistance, are not competitive with private enterprise, and can be made available without interfering unduly with domestic programs.
**(b) Eligibility of suppliers; debarment period; causes for debarment; conditions for reinstatement; periodic review** The President shall issue and enforce regulations determining the eligibility of any person to receive funds made available under this chapter. A person may be suspended under such regulations for a temporary period pending the completion of an investigation and any resulting judicial or debarment proceedings, upon cause for belief that such person or an affiliate thereof probably has undertake
Source: Supplied U.S. Code snapshot — release unconfirmed · 22 U.S.C. § 2381
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
Congress makes the following findings:
(1) During the last 20 years, HIV/AIDS has assumed pandemic proportions, spreading from the most severely affected regions, sub-Saharan Africa and the Caribbean, to all corners of the world, and leaving an unprecedented path of death and devastation.
(2) According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), more than 65,000,000 individuals worldwide have been infected with HIV since the epidemic began, more than 25,000,000 of these individuals have lost their lives to the disease, and more than 14,000,000 children have been orphaned by the disease. HIV/AIDS is the fourth-highest cause of death in the world.
(3)
(A) At the end of 2002, an estimated 42,000,000 individuals were infected with HIV or living with AIDS, of which more than 75 percent live in Africa or the Caribbean. Of these individuals, more than 3,200,000 were children under the age of 15 and more than 19,200,000 were women.
(B) Women are four times more vulnerable to infection than are men and are becoming infected at increasingly high rates, in part because many societies do not provide poor women and young girls with the social, legal, and cultural protections against high risk activities that expose them to HIV/AIDS.
(C) Women and children who are refugees or are internally displaced persons are especially vulnerable to sexual exploitation and violence, thereby increasing the possibility of HIV infection.
(4) As the leading cause of death in sub-Saharan Africa, AIDS has killed more than 19,400,000 individuals (more than 3 times the number of AIDS deaths in the rest of the world) and will claim the lives of one-quarter of the population, mostly adults, in the next decade.
(5) An estimated 2,000,000 individuals in Latin America and the Car
Source: Supplied U.S. Code snapshot — release unconfirmed · 22 U.S.C. § 7611
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
Page 1992
TITLE 22—FOREIGN RELATIONS AND INTERCOURSE
§ 7653
as a nonvoting member. The Panel shall con-
sist of not more than 15 members (excluding
the Global AIDS Coordinator), to be appointed
by the Global AIDS Coordinator not later than
1 year after July 30, 2008, including—
(A) 2 members from the Department of
Health and Human Services with expertise
relating to the prevention of mother-to-child
transmission activities;
(B) 2 members from the United States
Agency for International Development with
expertise relating to the prevention of moth-
er-to-child transmission activities;
(C) 2 representatives from among health
ministers of national governments of foreign
countries in which programs under this
chapter are administered;
(D) 3 members representing organizations
implementing prevention of mother-to-child
transmission activities under this chapter;
(E) 2 health care researchers with exper-
tise relating to global HIV/AIDS activities;
and
(F) representatives from among patient
advocate groups, health care professionals,
persons living with HIV/AIDS, and non-gov-
ernmental organizations with expertise re-
lating to the prevention of mother-to-child
transmission activities, giving priority to
individuals in foreign countries in which
programs under this chapter are adminis-
tered.
(3) Duties of Panel
The Panel shall—
(A) assess the effectiveness of current ac-
tivities in reaching the target described in
subsection (b)(1);
(B) review scientific evidence related to
the
provision
of
mother-to-child
trans-
mission prevention services, including pro-
grammatic data and data from clinical
trials;
(C) review and assess ways in which the Of-
fice of the United States Global AIDS Coor-
dinator collaborates with international and
multilate
Source: Supplied 2024 U.S. Code historical extraction · 22 U.S.C. § 7653
Stored review status: historical_2024_not_currentness_verified. Same stored citation; legal effect and authority still require review.